Whole Genome Sequencing of Single-Circulating Tumor Cell Ameliorates Unraveling Breast Cancer Heterogeneity

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. doi:10.3322/caac.21442
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Zhang S, et al. Cancer incidence and mortality in China, 2013. Cancer Lett. 2017;401:63–71. doi:10.1016/j.canlet.2017.04.024
   PubMed Web of Science ®Google Scholar
• Zheng R, Zeng H, Zhang S, Chen W. Estimates of cancer incidence and mortality in China, 2013. Chin J Cancer. 2017;36:66. doi:10.1186/s40880-017-0234-3
   PubMedGoogle Scholar
• Huober J, Thurlimann B. The role of combination chemotherapy in the treatment of patients with metastatic breast cancer. Breast Care. 2009;4:367–372. doi:10.1159/000262808
   Web of Science ®Google Scholar
• Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017. Ann Oncol. 2017;28(8):1700–1712. doi:10.1093/annonc/mdx308
   PubMed Web of Science ®Google Scholar
• Bartsch R, Bergen E. ASCO 2018: highlights in HER2-positive metastatic breast cancer. Memo. 2018;11:280–283. doi:10.1007/s12254-018-0441-x
   Google Scholar
• Lianidou ES, Strati A, Markou A. Circulating tumor cells as promising novel biomarkers in solid cancers. Critical Reviews in Clinical Laboratory Sciences. 2014;51:160–171. doi:10.3109/10408363.2014.896316
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–791. doi:10.1056/NEJMoa040766
   PubMed Web of Science ®Google Scholar
• de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302–6309. doi:10.1158/1078-0432.CCR-08-0872
   PubMed Web of Science ®Google Scholar
• Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:3213–3221. doi:10.1200/JCO.2007.15.8923
   PubMed Web of Science ®Google Scholar
• Lee JS, Magbanua MJM, Park JW. Circulating tumor cells in breast cancer: applications in personalized medicine. Breast Cancer Res Treat. 2016;160:411–424. doi:10.1007/s10549-016-4014-6
   Web of Science ®Google Scholar
• Kim C, Paik S. Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol. 2010;7:340–347. doi:10.1038/nrclinonc.2010.61
   PubMed Web of Science ®Google Scholar
• Lohr JG, Adalsteinsson VA, Cibulskis K, et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014;32:479–484. doi:10.1038/nbt.2892
   PubMed Web of Science ®Google Scholar
• Katsios C, Roukos DH. Individual genomes and personalized medicine: life diversity and complexity. Per Med. 2010;7:347–350. doi:10.2217/pme.10.30
   PubMed Web of Science ®Google Scholar
• Gulbahce N, Magbanua MJM, Chin R, et al. Quantitative whole genome sequencing of circulating tumor cells enables personalized combination therapy of metastatic cancer. Cancer Res. 2017;77:4530–4541. doi:10.1158/0008-5472.CAN-17-0688
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36:2105–2122. doi:10.1200/JCO.2018.77.8738
   PubMed Web of Science ®Google Scholar
• Lin PP. Integrated EpCAM-independent subtraction enrichment and iFISH strategies to detect and classify disseminated and circulating tumors cells. Clin Transl Med. 2015;4:38. doi:10.1186/s40169-015-0081-2
   Google Scholar
• Zong C, Lu S, Chapman AR, Xie XS. Genome-wide detection of single-nucleotide and copy-number variations of a single human cell. Science. 2012;338:1622–1626. doi:10.1126/science.1229164
   PubMed Web of Science ®Google Scholar
• Joseph C, Papadaki A, Althobiti M, Alsaleem M, Aleskandarany MA, Rakha EA. Breast cancer intratumour heterogeneity: current status and clinical implications. Histopathol. 2018;73:717–731. doi:10.1111/his.13642
   Web of Science ®Google Scholar
• Navin N, Krasnitz A, Rodgers L, et al. Inferring tumor progression from genomic heterogeneity. Genome Res. 2010;20:68–80. doi:10.1101/gr.099622.109
   PubMed Web of Science ®Google Scholar
• Brouwer A, De Laere B, Peeters D, et al. Evaluation and consequences of heterogeneity in the circulating tumor cell compartment. Oncotarget. 2016;7:48625–48643. doi:10.18632/oncotarget.8015
   Google Scholar
• Stephens PJ, Tarpey PS, Davies H, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012;486:400–404. doi:10.1038/nature11017
   PubMed Web of Science ®Google Scholar
• Nik-Zainal S, Van Loo P, Wedge DC, et al. The life history of 21 breast cancers. Cell. 2012;149:994–1007. doi:10.1016/j.cell.2012.04.023
   PubMed Web of Science ®Google Scholar
• Almendro V, Kim HJ, Cheng YK, et al. Genetic and phenotypic diversity in breast tumor metastases. Cancer Res. 2014;74:1338–1348. doi:10.1158/0008-5472.CAN-13-2357-T
   PubMed Web of Science ®Google Scholar
• Amir E, Miller N, Geddie W, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol. 2012;30:587–592. doi:10.1200/JCO.2010.33.5232
   PubMed Web of Science ®Google Scholar
• Niikura N, Liu J, Hayashi N, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol. 2012;30:593–599. doi:10.1200/JCO.2010.33.8889
   PubMed Web of Science ®Google Scholar
• Lindström LS, Karlsson E, Wilking UM, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. Journal of Clinical Oncology. 2012;30:2601–2608. doi:10.1200/JCO.2011.37.2482
   PubMed Web of Science ®Google Scholar
• Singer CF, Balmaña J, Bürki N, et al. Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations. European Journal of Cancer. 2019;106:54–60. doi:10.1016/j.ejca.2018.10.007
   Web of Science ®Google Scholar
• Howie LJ, Scher NS, Amiri-Kordestani L, et al. FDA approval summary: pertuzumab for adjuvant treatment of HER2-positive early breast cancer. Clinical Cancer Research. 2018;2018:3003.
   Google Scholar
• Guan X, Ma F, Li C, et al. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. Cancer Commun. 2019;39:1. doi:10.1186/s40880-018-0346-4
   Web of Science ®Google Scholar
• Papadaki MA, Stoupis G, Theodoropoulos PA, Mavroudis D, Georgoulias V, Agelaki S. Circulating tumor cells with stemness and epithelial-to-mesenchymal transition features are chemoresistant and predictive of poor outcome in metastatic breast cancer. Mol Cancer Ther. 2019;18(2):437–447. doi:10.1158/1535-7163.MCT-18-0584
   PubMed Web of Science ®Google Scholar
• Clark TA, Chung JH, Kennedy M, et al. Analytical validation of a hybrid capture-based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA. J Mol Diagn. 2018;20:686–702. doi:10.1016/j.jmoldx.2018.05.004
   PubMed Web of Science ®Google Scholar
• Lanman RB, Mortimer SA, Zill OA, et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS One. 2015;10:e0140712. doi:10.1371/journal.pone.0140712
   PubMed Web of Science ®Google Scholar